Phentolamine is a reversible competitive α-adrenergic antagonist with similar affinities for α1 and α2 receptors. It has a long history of safe clinical use, and was developed as a potential therapy for male erectile dysfunction because of its capacity to increase the arteriolar blood flow to the corpora cavernosa. Phentolamine mesylate was administered to rats by oral gavage at daily doses of 10, 50, and 150 mg/kg for 24 months. A doserelated increase in mortality, ascribed to an exaggerated pharmacologic effect, was seen at high doses. Systemic exposure as measured by plasma drug concentration increased with dose and duration of dosing and slight drug accumulation occurred, particularly in high-dose males. In the treated groups, 10 males and 1 female were diagnosed with hibernomas, neoplasms of brown adipose tissue, which appeared in the thoracic cavity or retroperitoneal area as circumscribed, tan to reddish-brown lobulated masses. Histologically, the masses were well circumscribed with variably sized lobules defined by a rich capillary network and consisted of closely apposed oval to polygonal cells with large amounts of cytoplasm and a centrally located nucleus. The cytoplasm's appearance varied from multivacuolated to univacuolated to granular eosinophilic. In a few cases, neoplastic emboli were observed in capsular vessels. Ultrastructurally, the neoplastic cells contained numerous mitochondria with transverse parallel cristae that occupied over 60% of the cytoplasm and lipid droplets. This study documents the previously unreported development of hibernomas in rats treated with phentolamine mesylate.
INTRODUCTION
Phentolamine has been approved in the United States since 1950 for the management of hypertension and has a long history of safe pharmacologic human use. It is a reversible, competitive α-adrenergic antagonist that has similar affinities for α1 and α2 receptors. Its primary pharmacologic activity is to lower blood pressure through vasodilatation. Because of phentolamine's ability to induce a marked increase in arteriolar blood flow to the corpora cavernosa the mesylate salt was developed as a potential therapy for male erectile dysfunction (Zorgniotti, 1994) . Phentolamine mesylate is not genotoxic, as evidenced by negative results in the bacterial mutagenicity (Ames) assay (Wagner and Klug, 1999) , in vitro chromosome aberration assay in CHO cells (Putnam, 1988) and in vivo mouse micronucleus assay (Mitchell, 1997) . Oral doses of 75, 150, and 300 mg/kg were well tolerated by rats in the 1-month toxicity study (Blanset, 1996) . Similarly, no abnormal histopathologic findings suggesting proliferation of brown fat tissue were noted in rats at doses of 30, 100, and 300 mg/kg and of 75, 150, and 300 mg/kg in 3-and 6-month studies, respectively (Blanset, 1997a (Blanset, , 1998 . Chronic 6-month dosage was also well tolerated in dogs (Blanset, 1997b) . Finally, neither test article-related toxicity nor neoplasms were demonstrated in the 26-week p53 mouse carcinogenicity study at doses of 15, 45, and 150 mg/kg (Wenk, 1998) . Thus unexpectedly, during the 2-year rat carcinogenicity bioassay, hibernomas, neoplasms of brown adipose tissue, were diagnosed in 11 rats treated with phentolamine mesylate.
Hibernomas are rare, although well-characterized neoplasms of brown adipose tissue (BAT) that occur in humans and animals. Since the first description of this tumor in 1905, only approximately 110 cases have been reported in humans (Chitoku et al., 1998; Lele et al., 2002) and even fewer cases have been described in animals (Valerio et al., 1968; Ochoa, 1972; Coleman, 1980; Al Zubaidy and Finn, 1983; Murphy et al., 1986; Stefanski et al., 1987; Fox et al., 1989) . In rats, 1 laboratory reported an incidence of 3 hibernomas in 3,200 over a 4-year period (Al Zubaidy and Finn, 1983 ). The term "hibernoma" was coined to reflect the homology between the tumor cells and those of the interscapular gland of hibernating mammals, in which BAT was first identified. Smaller depots of BAT form the counterpart of the hibernating gland in nonhibernating species, including man. In all, BAT is the most important organ in nonshivering thermogenesis as it uncouples the oxidation of fatty acids from the production of ATP to dissipate this energy as heat (Himms-Hagen, 1985) . The phenoypic attributes at the basis of BAT thermogenic capacity, such as UC-(uncoupled)-type mitochondria, biochemical composition and metabolic activity, have long been considered to be tissue-specific. But the recent demonstration that traditional WAT-(white adipose tissue) adipocytes could be induced to acquire UCP (uncoupling protein) in BAT-type mitochondria has zeroed in on the dynamic nature of adipose tissue phenotypes (Cousin et al., 1992) .
Underscoring the plasticity of BAT, hyperplasia of BAT occurred in cold-stressed humans and rats (Huttunen et al., 1981; Himms-Hagen, 1985; Tsukazaki et al., 1995) , in humans with pheochromocytoma (Ricquier et al., 1982) and under severe hypoxemic conditions (Teplitz and Chan Lim, 1974) and in rats after administration of noradrenaline, isoproterenol or β3-adrenergic agonists (Himms-Hagen, 1985; Geloen et al., 1988; Nagase et al., 1994; Klaus et al., 1995; Tsukazaki et al., 1995) . Proliferation of BAT has been known for some time to be controlled by the sympathetic nervous system and β-adrenergic pathways, particularly via the β3adrenoceptor (Himms-Hagen, 1985; Nagase et al., 1994; Klaus et al., 1995; Tsukazaki et al., 1995) . Most recently, the identification of a mineralocorticoid receptor in brown adipocytes has added a new player, aldosterone, in the regulation of BAT (Zennaro et al., 1998) . As expected with rare tumors, little is known about development of hibernomas. In humans, 1 case occurred following corticosteroid treatment (Perling et al., 1988) . Specific chromosomal rearrangements in chromosome 11 in other cases suggested that genes in that location play a role either in tumor initiation or progression (Mertens et al., 1994) .
Here we describe the occurrence of hibernomas in phentolamine mesylate-treated rats during the 2-year carcinogenicity study. Additional studies addressing the mechanisms that led to the proliferation of brown fat are reported separately (Iatropoulos et al., 2003) .
MATERIAL AND METHODS

Animals and Husbandry
Studies were conducted at Huntingdon Life Sciences, East Millstone, NJ, a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and were in compliance with U.S. Food and Drug Administration Good Laboratory Practice regulations, with the NIH Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. A total of 260 male and 260 female VAF/Plus CD (Sprague-Dawley-derived) [Crl:CD BR] rats were obtained from Charles River Laboratories, Kingston, NY. At the initiation of the study, the rats were 6 weeks old and weighed between 120 and 215 g. They were housed individually in stainless steel cages in an environmentally controlled room (temperature 20 ± 5 • C, relative humidity 50 ± 20%) with a 12-hour light cycle and provided ad libitum access to Certified Rodent Diet No. 5002 (PMI Feeds, Inc., St Louis, MO) and drinking water. The rats were assigned to 4 different treatment groups each consisting of 65 males and 65 females using a balanced random allocation scheme based on body weight.
Test Article and Study Design
Phentolamine mesylate (Zonagen, Inc., The Woodlands, TX) was dissolved in distilled water and administered by oral gavage at daily doses of 10, 50, and 150 mg/kg for the duration of the study. Phentolamine mesylate concentrations in the dosing solutions were 2, 10, and 30 mg/mL for each dosing group, respectively. Analysis of dosing solutions used during the first 4 weeks of the study and monthly thereafter demonstrated that phentolamine mesylate concentrations in the dosing solutions were within 4% of the intended concentrations at all dose levels. Control rats received vehicle only. Clinical observations were made daily, and body weights and food consumption were recorded weekly through the first 13 weeks, and every 4 weeks thereafter. Blood sam-pling for hematology, coagulation assays, and serum chemistry were performed on 20 males and females per group at 6 and 12 months and at termination.
Plasma Drug Analysis
Plasma concentrations of phentolamine mesylate were determined in EDTA-containing-blood samples obtained from the orbital (retrobulbar) sinus on days 1, 182, and 371 and from the abdominal aorta at termination. There were 5 rats/sex/group/timepoint at 15 and 30 minutes, 1, 2, 4, 8, and 24 hours postdose.
Pathology
After an overnight fast, rats were exsanguinated following carbon dioxide inhalation and a complete necropsy was conducted. Absolute and relative weights (to body weight) of the adrenal glands, brain, heart, kidneys, liver, thymus, thyroid gland, testes (with epididymides), ovaries, and pituitary gland were recorded. All tissues/organs were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 3-5 µm and stained with hematoxylin and eosin (H&E). Grimelius for the demonstration of neurosecretory granules and reticulin stain were performed on representative sections of neoplasms as appropriate. To confirm the diagnosis of hibernoma, the 6 best preserved tumors (rat Nos. 2018M, 2026M, 4017M, 4038M, 2009M, and 3024M) were further processed for transmission electron microscopic examination. Briefly, formalin-fixed samples were subsequently fixed in sodium cacodylate-buffered 2.5% glutaraldehyde. Following postfixation in 2.0% buffered osmium tetroxide, the samples were rinsed, dehydrated through a graded series of ethanols, and cleared in 2 changes of propylene oxide. Two changes of propylene oxide/resin were completed before the samples were embedded in resin. Sections were cut at 60-90 nm, stained with uranyl acetate and lead citrate, and examined on a Philips CM10 transmission electron microscope.
Statistical Analyses
Body weight and food consumption data were analyzed by 2-way ANOVA and Dunnett's test followed by standard linear regression analysis. Hematology, clinical chemistry and organ weight data were evaluated using 1-way ANOVA and Dunnett's test. Survival data were analyzed for each sex separately by the series of programs included in the National Cancer Institute package for time to death. An assessment of mortality was made by the Kaplan-Meier method. Tumor evaluation (tumor types, incidence, survivorship, and time to tumor) was performed according to Peto analysis.
RESULTS
A dose-related increase in mortality (Table 1) was seen in males and females that resulted in early study termination. All surviving males at 150 mg/kg were sacrificed during week 90; treatment for the remaining groups of males was ceased after 96 weeks in an attempt to prolong survival and, because of continuing mortality, males were sacrificed at week 100. All surviving females were sacrificed at week 101. A cause of death could not be established based on postmortem examination for a large number of males at 150 mg/kg and 560 POULET ET AL.
TOXICOLOGIC PATHOLOGY the morbidity was thus ascribed to an exaggerated pharmacologic effect. Clinical signs in the high-dose rats included a high incidence of yellow ano-genital staining, indicative of unkempt condition and failure to groom, and high-dose males and females exhibited an increased incidence of rales and labored breathing. Food consumption was increased in all treated males and in females at 150 mg/kg for the first year and in high-dose males and females thereafter. Despite the increase in food consumption, up to 7% decrease in body weight was noted in males at 150 mg/kg from week 37 through termination. There were no significant effects of phentolamine mesylate administration on hematology and coagulation values. Consistent increases occurred over time between 6 and 12 months in the values of alkaline phosphatase, creatinine, protein (globulin), calcium and phosphorus (data not shown) mainly in males and females at 150 mg/kg. Toxicokinetic data demonstrated that the plasma concentration of phentolamine mesylate in male and female rats increased with dose and with duration of dosing throughout the study, albeit in a dose-disproportional way for males at 50 and 150 mg/kg and females at 150 mg/kg (Table 2 ). Repeated dosing resulted in drug accumulation, as evidenced by a trend toward an increase in C max and AUC values, longer NC-not calculated due to lack of sufficient data. a n = 2 for this group.
half-life and a decrease in clearance time, which suggested saturation of elimination. Thus, phentolamine mesylate had a longer residence time in both male and female rats as the duration of dosing and the dose increased, with male rats at 150 mg/kg having even a higher level of drug accumulation than females (3.7 times higher for males at 12 months compared to 1.9 times higher for females). In light of the pharmacokinetic data, the increased mortality of male rats as the study progressed may be a function of the increased exposure of males to phentolamine mesylate as compared to exposure in female rats.
Organ weight values were obtained from all rats at terminal necropsy, however, the early termination of the males at 150 mg/kg should be noted when interpreting these data. Alterations in organ weights (absolute and relative weights) consisted of (1) dose-related increases of about 20 to 40% in adrenal gland weights in males at 50 mg/kg and in both sexes at 150 mg/kg compared to controls; (2) severely (70%) lower thymus weights in males at 150 mg/kg and (3) about 20 and 30% increases in liver weights in females at 50 and 150 mg/kg, respectively. Histopathologic correlates were observed for the changes in the adrenal glands, thymus, and liver (see later). In addition, the following 2 organ weight changes Vol. 32, No. 5, 2004 PHENTOLAMINE MESYLATE-INDUCED HIBERNOMAS 561 did not have any histopathologic correlates: (1) slightly lower kidney weights in males at 150 mg/kg and (2) about 15 to 20% increases in heart weights in females at 150 mg/kg.
A small number of phentolamine mesylate-related neoplastic and nonneoplastic findings were noted (Table 3) . Eleven masses in the thoracic cavity or in the retroperitoneal area were upon microscopic evaluation diagnosed as hibernomas and ascribed to phentolamine mesylate administration. Hibernomas, a rare neoplasm of brown adipose tissue, were observed at all doses in phentolamine mesylate-treated rats. There was a slight increase in the incidence of hepatocellular neoplasms in treated females with the highest dose assuming the highest value, although still remaining within the known historical control range. Similarly, adenomas of the pars distalis of the pituitary gland also showed a slightly higher incidence in treated rats compared to controls, while still remaining within the range of historical control values. Phentolamine mesylate-related nonneoplastic findings consisted of hypertrophy/hyperplasia of the zona glomerulosa of the adrenal glands in males at all doses and in females at 150 mg/kg, squamous metaplasia of the nasal pharynx and/or eustachian tube in both sexes at all doses and basophilic altered cell foci in the liver in females at 50 and 150 mg/kg.
Hibernomas were circumscribed, tan to reddish-brown lobulated masses with variably firm to friable consistency, ranging in size from 2 × 1 cm for the smallest one to 5 × 6.5 cm for the largest. Many had multiple adhesions to the thoracic wall, visceral pleura, or lungs. They occurred almost exclusively in male rats with the exception of 1 female at 10 mg/kg, and were located in the thoracic cavity anterior mediastinum of 10 rats and in the retroperitoneal area of one. Their occurrence was not dose-or time-dependent. At histopathologic examination, all neoplasms consisted of variably sized lobules of closely apposed, large, oval to polygonal cells intimately associated with abundant capillaries.
Both the lobulation and the rich vascular network were highlighted by reticulin stain. The neoplastic cells contained large amounts of cytoplasm and a centrally located, round to oval nucleus with finely granular chromatin and an occasional nucleolus. The appearance of the cytoplasm ranged from granular eosinophilic to "foamy" or multivacuolated, due to the presence of variable numbers of small optically empty vacuoles. A few signet ring-appearing cells (univacuolated) displaying one huge vacuole that displaced the nucleus to the periphery were also observed. In each tumor, the population of neoplastic cells consisted of a random mixture of different proportions of granular eosinophilic, multivacuolated or univacuolated cells. Tumor cell morphology, as based on the degree of cytoplasmic vacuolation, was modified in individual neoplasms in a dose-related fashion from the 10 mg/kg to the 150 mg/kg dose groups (Figure 1) . Multivacuolated, univacuolated and granular eosinophilic cells characterized the tumors at all doses, but the former 2 clearly predominated at 10 and 50 mg/kg (Figures 1a and b) . At 10 mg/kg, univacuolated cells were most numerous and granular eosinophilic cells were rare. In contrast, granular eosinophilic cells were particularly prominent at 150 mg/kg, especially in 4017M, where they conferred a hepatoid appearance to the tumor (Figure 1c ). Mitoses, infrequent at 10 and 50 mg/kg, became evident at 150 mg/kg and abounded in 4017M, where they accompanied a high degree of cellular and nuclear pleomorphism. Results of the Grimelius stain were negative.
Where natural boundaries were available for examination, the tumors were well demarcated from the adjacent normal adipose or pulmonary tissue and some were partially encapsulated by a moderately thick fibrous capsule. In a few cases, short anastomosing collagen bands separated the mass into irregular nodules. Large blood vessels were often thrombosed within these septa. Small areas of hemorrhage and coagulative necrosis were scattered multifocally throughout the neoplasms in the 10 mg/kg dose group. These areas became larger in the 150 mg/kg dose group and particularly extensive in the retroperitoneal mass of 4052M. Also, large sections of the tumor were infarcted in 1 male (3054M) at 50 mg/kg. Clusters of pigment-laden macrophages and small numbers of lymphocytes were occasionally noted in the connective tissue capsule or septa. There was no evidence of local invasion of the adjacent adipose or pulmonary tissues or distant metastases. However, neoplastic emboli were present in the capsular vessels of one male at 50 mg/kg (3054M) and of the 3 males at 150 mg/kg (Figure 2) .
On electron microscopic examination, all six neoplasms exhibited similar ultrastructural features (Figures 3-5 ). Neoplastic cells were packed with innumerable mitochondria, which occupied well over 60% of the cytoplasm in the highdose rats (Figures 3 and 4) . The mitochondria appeared round, with abundant transverse, parallel lamellar cristae. Vesicular and/or concentric cristae occurred occasionally in 4017M and were particularly prominent in 2018M. Small intramatrical densities, present in a few mitochondria in 4017M, were common in 2018M (Figure 3 ). In addition, tumor cells contained variable numbers of lipid droplets, which corresponded, undoubtedly, to the optically empty intracytoplasmic vacuoles seen by light microscopy. As expected from the light microscopic appearance, only a few, usually small, lipid droplets were observed in tumor cells from the 150 mg/kg dose group (Figure 4) . In contrast, the lipid droplets present in tumor cells from the lower dose groups were larger and more numerous ( Figure 3) . The nucleus was centrally located, round, and mostly electron-lucent, with small amounts of marginated heterochromatin and an occasional nucleolus. Occasionally, convoluted nuclear membrane profiles were noted. Besides rare secondary lysosomes, very few other cytoplasmic organelles were readily discernible. Stacks of Golgi apparatus and profiles of endoplasmic reticulum were inconspicuous.
Adjoining cells had no visible intercellular junctions ( Figure 5) . A thin, faint linear accumulation of material continuous with the basal lamina of endothelial cells appeared to surround at places the plasma membrane of neoplastic cells. The suboptimal preservation of the samples, however, rendered its definitive interpretation difficult. Rare focal densities were localized on the plasma membrane of 2 adjoining neoplastic cells in 4017M, suggesting possibly hemidesmosomes. In each tumor, 1 or 2 granulocytes were present in the lumen of a blood vessel or interposed between the vascular endothelial cells of the capillaries and the neoplastic cells. All 6 neoplasms examined by electron microscopy exhibited ultrastructural characteristics typical of BAT and a diagnosis of hibernoma was thus warranted based on the light and electron microscopy features.
In addition, a few nonneoplastic histopathologic changes occurred with a greater incidence in phentolamine mesylatetreated rats compared to controls. Minimal to moderate hypertrophy/hyperplasia of the zona glomerulosa was present in the adrenal cortex of males at all doses and females at 150 mg/kg, which correlated with the increased adrenal gland weights. There was a dose-related minimal to severe squamous metaplasia of the epithelium lining the nasopharynx and/or eustachian tube in both sexes at all doses. Subacute to chronic inflammatory exudate admixed with intraluminal eosinophilic material and cell debris accompanied the metaplastic changes, which were attributed to reflux secondary to the gavage procedure. In the liver, the incidence of foci of basophilic hepatocellular alteration was higher in females at 50 and 150 mg/kg compared to controls. In males, the incidence of this finding was comparable in the 0, 10, and 50 mg/kg groups; it was lower in the 150 mg/kg group due to decreased survivorship at that dose. Finally, thymic atrophy, interpreted as stress-induced, was seen in males at 150 mg/kg.
DISCUSSION
In a 2-year carcinogenicity assay of phentolamine mesylate, hibernoma, an unusual neoplasm of BAT, occurred in 3 males and 1 female at 10 mg/kg, 4 males at 50 mg/kg, and 3 males at 150 mg/kg (out of 65 rats/sex/group). The diagnosis of hibernoma was established based on the light and electron microscopic features of the tumors (Gaffney et al., 1983; Ghadially, 1988; Lele et al., 2002) . Differential diagnoses for eosinophilic granular cell tumors include oncocytomas, granular cell myoblastomas, rhabdomyomas, paragangliomas, neuroendocrine tumors, and oncocytic carcinoids. The absence of membrane-bound, dense core neurosecretory granules in the tumors seen during the 2-year bioassay excluded paragangliomas, oncocytic carcinoid, and neuroendocrine tumors. The ultrastructural features observed in our cases, i.e., large numbers of mitochondria with parallel lamellar cristae, abundant lipid droplets, and few other cytoplasmic organelles, were typical of brown adipocytes. These features did not substantiate the diagnoses of oncocytomas (devoid of lipid droplets), granular cell myoblastomas (characterized by abundant lysosomes) and rhabdomyomas (myofilaments and Z lines).
The physiology of BAT is that of stimulation and regression, epitomized in seasonal variation in hibernating animals. But in humans and animals alike, circumstances such as prolonged exposure to cold, chronic hypoxemia, chronic sympathoadrenal activation, starvation, and chronic wasting diseases lead to hypertrophy and/or hyperplasia of the BAT (Teplitz and Chan Lim, 1974; Huttunen et al., 1981; Nagase et al., 1994; Tsukazaki et al., 1995) . Tumors, however, have 564 POULET ET AL. TOXICOLOGIC PATHOLOGY never been described to arise as a consequence of these disease states. Although many mechanisms of BAT stimulation remain to be elucidated, players include neuropeptides, sympathetic innervation, A-V anastomoses under sympathetic control, growth factors such as IGF-I and bFGF and hormones such as melatonin and mineralocorticoids (Himms-Hagen, 1985; Yamashita et al., 1994a; Yamashita et al., 1994b) . That the thermogenic and trophic responses of BAT are primarily controlled by sympathetic innervation and the action of noradrenaline is well-established (Himms-Hagen, 1985; Geloen et al., 1988; Nagase et al., 1994; Klaus et al., 1995; Tsukazaki et al., 1995) . Conversely, atrophy of BAT thermogenic capacity, histologically translated by an inactive WAT-like appearance, occurs under conditions of low sympathetic activity. As a nonselective α-adrenergic antagonist, phentolamine mesylate causes vasodilatation and thus hypotension by decreasing peripheral vascular resistance. Sympathoadrenal activation and reflex tachycardia ensue as a result of potent stimulation of β1 and β2 cardiac receptors to compensate for the decreased cardiac output and arterial pressure. To characterize the hemodynamic parameters following drug administration, a single-dose safety pharmacology study was conducted using 10 and 150 mg/kg of phentolamine mesylate (Watkins and Young, 1999) . Significant hypotension as evidenced by a drop of 35 mm Hg in magnitude was observed within 5 minutes after 150 mg/kg of phentolamine mesylate, and the heart rate increased markedly by an average of 88 beats/minute after 10 mg/kg and by 128 beats/minute after 150 mg/kg. Hibernomas were seen in this study in the presence of drug-induced toxicity and were associated with a physiologic response incompatible with long-term survival. Indeed, high mortality and clinical signs of rales and labored breathing underscore the significant hemodynamic effects induced by phentolamine mesylate at these doses in rats. Similarly, in earlier studies, 2 rats at 300 mg/kg and 1 at 150 mg/kg died within the first 2 weeks of dosing in the 1-month study (Blanset, 1996) , and 11 out of 40 rats and 19 out of 25 at 300 mg/kg died or were sacrificed in moribund condition in the 3-and 6-month studies, respectively (Blanset, 1997a (Blanset, , 1998 . In these studies, rales and/or labored breathing were also noted clinically and marked pulmonary congestion was seen histologically, suggesting that phentolamine pharmacologic action of vasodilatation of blood vessels with consequent pooling of the blood in the pulmonary vasculature played a role in the rats' morbidity. It is well known that stimulation and/or hyperplasia of BAT occur under conditions of hypothermia and chronic noradrenergic stimulation (Himms-Hagen, 1985) . In the course of the 2-year bioassay, hypothermia may have resulted in these rats as a consequence of the drug-induced hypotension. In addition, chronic sympathoadrenal activation compensated for the decreased cardiac output and arterial pressure. Finally, the nonneoplastic finding of hypertrophy/hyperplasia of the zona glomerulosa of the adrenal glands in male rats at 10, 50, and 150 mg/kg suggests that the aldosterone system was stimulated. These avenues open up the possibility that reactivation and hyperplasia of the BAT may have arisen in these rats following chronic stimulation by 1 or several factors of which many (norepinephrine, aldosterone) were adaptive measures in response to the drug-induced hypotension. Over the entire life span of the rats, excessive stimulation led probably to dereg-ulation of hyperplasia and neoplastic transformation. This would be, to our knowledge, the first example of induction of hibernomas following pharmacologically mediated physiologic changes.
Other neoplastic findings in this study included slight increases in the incidence of hepatocellular adenomas in females and that of adenomas of the pars distalis of the pituitary gland in both sexes although more pronounced in females. This gender difference can be explained by the low survival rate of males at the high-dose. For both neoplasms, the incidence observed in this study remained within the range of historical control values. Compared to those, the incidence of pituitary adenomas in concurrent control females was exceptionally low. However, the reason for the slight increased incidence in rats receiving phentolamine mesylate compared to concurrent controls is unknown.
With the exception of 1 case report of a hibernoma following corticosteroid treatment (Perling et al., 1988) , only troglitazone, a thiazolidinedione that binds and activates the peroxisome proliferator-activated receptor gamma, has been associated with hyperplastic changes in the BAT (Breider et al., 1999; Herman et al., 2002) . However, in the case of troglitazone an increase in cell proliferation in the BAT was demonstrated by BrdU immunohistochemistry after 14 days of treatment, indicating a direct effect of the thiazolidinedione on BAT (Breider et al., 1999) . This is in contrast with our studies of phentolamine mesylate in which there were no abnormal findings, suggesting proliferation of BAT, in shorter-term studies. Absence of hyperplastic changes in BAT at earlier time points supports the hypothesis that hibernomas develop only after continuous, prolonged insult/desequilibrium of trophic factors brought about by phentolamine mesylate treatment. Indeed, the earliest tumor was discovered after 37 weeks of dosing, emphasizing the probable need for prolonged stimulation of BAT for tumorigenesis. There were no histopathologic findings in the 26-week p53 mouse bioassay at doses up to 150 mg/kg (Wenk, 1998) . This suggests that either the mouse is insensitive to the development of hibernomas under these conditions or, alternatively, that insufficient time had elapsed to allow for tumor development. Systemic exposures appeared roughly similar in both rat and mouse species. Indeed systemic exposure for the 150 mg/kg dose was equivalent to 33-and 24 times the 80 mg human dose in mice and rats, respectively. In the 2-year rat bioassay, the pharmacokinetic data indicated increased systemic exposure with dose throughout the study, with drug accumulating in males at 50 and 150 mg/kg and in females at 150 mg/kg as a result of saturation of elimination. The higher dose disproportionality in males compared to females may explain the mortality and the occurrence of hibernomas preferably in males compared to females. However, the fact that the development of hibernomas in treated males does not appear dose-related cannot be addressed in light of the pharmacokinetic data alone when systemic exposure to phentolamine mesylate increased with dose throughout the study.
Hibernomas are usually considered benign tumors in humans where malignant cases are exceptional (Teplitz et al., 1980) . In contrast, out of the 9 cases reported in laboratory rats, evidence of malignancy was present in many as local invasion, distant neoplastic emboli, and high mitotic rate (Coleman, 1980; Al Zubaidy and Finn, 1983; Stefanski et al., Vol. 32, No. 5, 2004 PHENTOLAMINE MESYLATE-INDUCED HIBERNOMAS 565 1987 . This discrepancy may be explained by species-specific differences in tumor biology, or, alternatively, it may reflect the fact that neoplasms in rats are allowed their natural progression towards malignant transformation. In this study, tumor cells from the high-dose group exhibited a more densely staining eosinophilic cytoplasm with fewer lipid droplets and a higher degree of malignancy such as cellular pleomorphism, anaplasia, and vascular invasion compared to those of midand low-dose groups, which may suggest greater stimuli at higher doses. Norepinephrine's role in stimulating lipolysis and oxidative metabolism, reflected on a cellular level by oncocytic cellular appearance with tiny lipid vacuoles, has been well demonstrated in response to cold in order to increase heat production (Himms-Hagen, 1985) . Thus, the difference in morphology and abundance of lipid droplets in tumor cells of the low-, mid-, and high-dose groups may be explained by progressively greater norepinephrine influence as doses increased. Unfortunately, catecholamine levels were not measured in rats receiving phentolamine mesylate in the 2-year bioassay.
In conclusion, phentolamine mesylate induced the development of hibernomas in a non-dose-related fashion in the 2-year rat bioassay. Because phentolamine mesylate is not genotoxic and because it induces profound hemodynamic alterations due to its pharmacologic action, the mechanism of tumor formation was considered to result epigenetically from the chronic adaptive responses of the rat secondary to the pharmacodynamic effect of phentolamine mesylate at these doses.
